Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited has received approval from China’s National Medical Products Administration for a supplementary drug application related to the marketing authorization transfer of esmolol hydrochloride injection. This approval marks a significant step for the company, following a technology transfer agreement with Beijing Minkang Baicao Pharmaceutical Technology. Investors may find this development noteworthy as it strengthens Xinhua Pharmaceutical’s position in the pharmaceutical market.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.